HomeCompareKAEPY vs ABBV

KAEPY vs ABBV: Dividend Comparison 2026

KAEPY yields 2.34% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $78.8K in total portfolio value
10 years
KAEPY
KAEPY
● Live price
2.34%
Share price
$8.54
Annual div
$0.20
5Y div CAGR
2.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$340.30
Full KAEPY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — KAEPY vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKAEPYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KAEPY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KAEPY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KAEPY
Annual income on $10K today (after 15% tax)
$198.97/yr
After 10yr DRIP, annual income (after tax)
$289.26/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,766.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KAEPY + ABBV for your $10,000?

KAEPY: 50%ABBV: 50%
100% ABBV50/50100% KAEPY
Portfolio after 10yr
$63.0K
Annual income
$12,556.03/yr
Blended yield
19.94%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

KAEPY
No analyst data
Altman Z
1.2
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KAEPY buys
0
ABBV buys
0
No recent congressional trades found for KAEPY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKAEPYABBV
Forward yield2.34%3.06%
Annual dividend / share$0.20$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR2.1%40.6%
Portfolio after 10y$23.6K$102.3K
Annual income after 10y$340.30$24,771.77
Total dividends collected$2.9K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KAEPY vs ABBV ($10,000, DRIP)

YearKAEPY PortfolioKAEPY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,939$239.00$11,550$430.00$611.00ABBV
2$11,954$249.47$13,472$627.96$1.5KABBV
3$13,051$260.14$15,906$926.08$2.9KABBV
4$14,236$271.01$19,071$1,382.55$4.8KABBV
5$15,514$282.07$23,302$2,095.81$7.8KABBV
6$16,894$293.32$29,150$3,237.93$12.3KABBV
7$18,381$304.77$37,536$5,121.41$19.2KABBV
8$19,984$316.42$50,079$8,338.38$30.1KABBV
9$21,711$328.26$69,753$14,065.80$48.0KABBV
10$23,571$340.30$102,337$24,771.77$78.8KABBV

KAEPY vs ABBV: Complete Analysis 2026

KAEPYStock

The Kansai Electric Power Company, Incorporated engages in electricity, gas and heat supply, and telecommunication businesses in Japan. It operates through four segments: Energy Business, Power Transmission and Distribution Business, Information and Communication Business, and Life and Business Solution Business. The company generates power from thermal, hydropower, wind, biomass, and nuclear power generation plants. It is also involved in the power transmission and distribution business; provision of information and communication services for homes and businesses under the eo Hikari brand; mobile business under the mineo business; corporate solution business; and real estate leasing, sale, and management activities; and leisure, leasing, call center management, dispatching, medical health care, and home security businesses. In addition, the company engages in the maintenance and construction of power distribution and electricity lines, thermal and nuclear power generation facilities, and information and communication equipment; utility pole advertising; manufacture, supply, and sale of gas; manufacture and sale of power distribution equipment, such as overhead wire hardware, insulators/bushings, steel pipe columns, concrete columns, etc.; housing equipment sales; remodeling work; and passenger/freight transportation. Further, it is involved in the survey and research on safety technology for nuclear power generation, survey/design /construction supervision related to civil engineering/architecture, etc.; acceptance/ storage/vaporization /delivery of LNG; condominium high-voltage batch power reception service business; fuel trading and transportation; corporate settlement; and provision of survey, analysis, consulting, and construction services related to the environment, civil engineering, and architecture, as well as public relations and engineering services The Kansai Electric Power Company, Incorporated was founded in 1951 and is headquartered in Osaka, Japan.

Full KAEPY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this KAEPY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KAEPY vs SCHDKAEPY vs JEPIKAEPY vs OKAEPY vs KOKAEPY vs MAINKAEPY vs JNJKAEPY vs MRKKAEPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.